Related references
Note: Only part of the references are listed.Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an In Vitro Pharmacodynamic Model
Maya Beganovic et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
In vitro Bactericidal Activities of Combination Antibiotic Therapies Against Carbapenem-Resistant Klebsiella pneumoniae With Different Carbapenemases and Sequence Types
Jocelyn Qi-Min Teo et al.
FRONTIERS IN MICROBIOLOGY (2021)
In vitro and in vivo Activity of Combinations of Polymyxin B with Other Antimicrobials Against Carbapenem-Resistant Acinetobacter baumannii
Hui Zhang et al.
INFECTION AND DRUG RESISTANCE (2021)
Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B-based combination therapy
Nayara Helisandra Fedrigo et al.
SCIENTIFIC REPORTS (2021)
Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysis
Jovan Borjan et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae
Su Mon Aye et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Evaluation of polymyxin B in combination with 13 other antibiotics against carbapenemase-producing Klebsiella pneumoniae in time-lapse microscopy and time-kill experiments
P. Wistrand-Yuen et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
International Consensus Guidelines for the Optimal Use of the Polymyxins Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)
Brian T. Tsuji et al.
PHARMACOTHERAPY (2019)
Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Acinetobacter baumannii Using Checkerboard Information
Thatiany Cevallos Menegucci et al.
MICROBIAL DRUG RESISTANCE (2019)
Ceftazidime/avibactam Improves the Antibacterial Efficacy of Polymyxin B Against Polymyxin B Heteroresistant KPC-2-Producing Klebsiella pneumoniae and Hinders Emergence of Resistant Subpopulation in vitro
Xingyan Ma et al.
FRONTIERS IN MICROBIOLOGY (2019)
Synergy of polymyxin B, tigecycline and meropenem against carbapenem-resistant Enterobacter cloacae complex isolates
Paola Hoff Alves et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2019)
Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection
Gregory Saraiva Medeiros et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae
Sarath Nath et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Avibactam Pharmacokinetic/Pharmacodynamic Targets
Wright W. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections
Matt Shirley
DRUGS (2018)
Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae
John K. Diep et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model
Yiying Cai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae
Joshua T. Thaden et al.
VIRULENCE (2017)
Attributable Mortality of Healthcare-Associated Infections Due to Multidrug-Resistant Gram-Negative Bacteria and Methicillin-Resistant Staphylococcus Aureus
Richard E. Nelson et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2017)
Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes
Laurent Poirel et al.
CLINICAL MICROBIOLOGY REVIEWS (2017)
In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B
Yiying Cai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Agents of Last Resort Polymyxin Resistance
Keith S. Kaye et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2016)
New β-Lactamase Inhibitors in the Clinic
Krisztina M. Papp-Wallace et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2016)
Polymyxin: Alternative Mechanisms of Action and Resistance
Michael J. Trimble et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae
Maria J. B. Melchers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections
Maria Helena Rigatto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro Activity of Ceftazidime-Avibactam Combination in In Vitro Checkerboard Assays
Johanna Berkhout et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Multidrug-resistant Gram-negative bacteria in solid organ transplant recipients with bacteremias
Q. Q. Wan et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2015)
Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort
L. E. Lopez-Cortes et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Early Insights into the Interactions of Different β-Lactam Antibiotics and β-Lactamase Inhibitors against Soluble Forms of Acinetobacter baumannii PBP1a and Acinetobacter sp PBP3
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase Inhibitor
Therese Stachyra et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor
A Bonnefoy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Share Paper
